A user is seeking advice on adding dutasteride to their finasteride regimen to stop DHT-related scalp itch. They have tried selenium sulfide and ketoconazole shampoos with temporary success.
PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.
Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.
Tretinoin alone has led to hair regrowth in the temples and hairline. The user is considering oral minoxidil or dutasteride but prioritizes health first.
The user experienced hair thinning from chromium and alpha lipoic acid supplements, which stopped after discontinuing them. Someone mentioned this could be telogen effluvium, a temporary condition.
Post Finasteride Syndrome (PFS) may result from epigenetic changes and gut microbiota alterations. Supplementing with Allopregnanolone might protect against these adverse effects.
Switching from propylene glycol to glycerin in topical finasteride may reduce systemic absorption and side effects while maintaining local scalp DHT suppression. Concerns exist about glycerin's ability to deliver the full dose to hair follicles.
Baldness is difficult to cure because current treatments like finasteride, dutasteride, and minoxidil only prevent hair shedding, and new developments are mostly ineffective. Botox shows potential in aiding skin regeneration and hair growth, but maintenance therapy with treatments like dutasteride and minoxidil may still be necessary.
Hair cloning and injection of dermal papilla cells are discussed, with skepticism about their availability by 2023. Users mention Minoxidil, finasteride, and hair transplants as current treatments.
The user is experiencing hair thinning and brittleness, possibly due to Telogen Effluvium, which affects body hair and may be linked to stress or nutrition. They are considering using finasteride for treatment but are unsure if it will address their symptoms.
HMI 115 did not work as expected for hair regrowth in humans, unlike in macaque monkeys. There is anticipation for further research on prolactin's role in hair loss, with expectations that pharmaceutical companies will likely solve this before universities.
The user is considering a second hair transplant or scalp micropigmentation to address thinning in the crown area and hide scars from a previous transplant. They have been using finasteride and minoxidil for three years but are concerned about the appearance of their donor area and the effectiveness of scalp micropigmentation.
The user experienced hair thinning despite using Dutasteride, topical Minoxidil, Finasteride, and Ketoconazole shampoo, but noticed improvement after adjusting their diet and vitamin intake. They plan to continue their routine and monitor changes while addressing dandruff issues.
The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.
An 18-year-old experiencing diffuse hair thinning since 8th grade seeks advice. They are concerned about having less hair than their 52-year-old father and are looking for treatment options.
Elastin-based peptides may help reduce wrinkles and could potentially benefit the scalp. The conversation suggests using them with hyaluronic acid gel to improve scalp health and reduce hair fall.
The individual is experiencing hair loss due to insulin resistance (IR) and is seeking advice. They are currently using a keto diet, supplements, exercise, and plan to add metformin to their regimen.
The conversation is about trying DS Labs SOD supplements for hair loss, which contain ingredients like Genistein, B-sitosterol, and Biotin. The user is considering adding these supplements to their existing hair care routine.
The conversation is about the best vehicle for RU58841, comparing trichosol and Garnier/Vichy Stemoxydine, avoiding propylene glycol (PG) or ethanol due to previous scalp damage. The user is also seeking sources for these products in the EU.
The conversation is about the correct usage of a hair serum containing redensyl, procapil, capixil, and baicapil. The user is seeking advice on the amount to apply and whether washing hair after application is necessary.
The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.
A user experienced continuous hair shedding for six months after using topical 5% minoxidil and 0.1% finasteride. They switched to minoxidil gel and oral finasteride 1 mg due to scalp itchiness and are seeking advice on their situation.
The conversation discusses using GFM Gel, a topical gel with polypeptides that mimic growth factors to promote hair regrowth and strengthen hair. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.
A user is considering switching from oral minoxidil to a combination of 5% topical minoxidil and tretinoin to reduce hypertrichosis. They hope this combination will be effective without causing excessive body hair growth.
A 12-year-old diagnosed with alopecia shares their experience and current treatments, including Dermovate, an unnamed cream, and liquid iron. The community offers support and encouragement.
The user is using Finasteride gel and considering adding Redensyl to their routine, along with weekly microneedling, but is hesitant to use Minoxidil due to its initial shedding phase. They seek advice on the safety and ideal routine for combining these treatments.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
Redensyl, a hair loss treatment that has been claimed to be 80% more effective than minoxidil, but users have not experienced any results from using it.
The user has been using oral minoxidil and dutasteride for hair loss without success and is considering adding topical 17Ξ±-estradiol, Pyrilutamide, Clascoterone, or cetirizine. They have confirmed low serum DHT levels and are exploring additional treatments due to genetic sensitivity to DHT and prostaglandin D2.